We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Oncology

Journal Scan / Research · January 30, 2020

Gemcitabine and Cisplatin ± Veliparib for Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation

Journal of Clinical Oncology

 

Additional Info

Disclosure statements are available on the authors' profiles:

Journal of Clinical Oncology
Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation
J. Clin. Oncol 2020 Jan 24;[EPub Ahead of Print], EM O'Reilly, JW Lee, M Zalupski, M Capanu, J Park, T Golan, E Tahover, MA Lowery, JF Chou, V Sahai, R Brenner, HL Kindler, KH Yu, A Zervoudakis, S Vemuri, ZK Stadler, RKG Do, N Dhani, AP Chen, DP Kelsen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading